Publications by authors named "D Arulmoli Devi"
This work presents a density functional theory (DFT) study of substitutional and adsorption-based halogen (I or F) doping of WS-based transistors to enhance their contact properties. Substitutional doping of the WS monolayer with halogens results in -type behavior, while halogen adsorption on the surface of the WS monolayer induces -type behavior. This is attributed to differing directions of charge flow, as supported by the Mulliken analysis.
View Article and Find Full Text PDFArticle Synopsis
- * A study conducted from July to December 2023 analyzed the relationship between GDNF expression, serum levels, and cognitive functioning in 100 ASD patients compared to 40 healthy controls using various analytical techniques.
- * Results indicated that lower serum GDNF levels in ASD patients correlated with more severe cognitive deficits, as evidenced by lower Mini-Mental State Examination scores, suggesting reduced neuronal protection linked to the disorder.
Article Synopsis
- - Endotoxin contamination in MRI contrast agents can lead to immune reactions, raising concerns for patient safety, as there are stricter rules for implants and catheters than for these agents.
- - The study tested a chromogenic LAL assay to measure endotoxin levels in an MRI contrast agent produced in Malaysia, using water for injection to dissolve the powdered agent.
- - Results showed a high coefficient of efficiency (≥ 0.98) and endotoxin levels below the safe limit of 0.5 EU/mL, indicating that the contrast agent is unlikely to cause pyrogenic effects.
Article Synopsis
- Myxoma is a rare, non-cancerous tumor that can occur in various body parts, including the scrotum, and can be either cutaneous or intramuscular.
- Scrotal myxomas, though infrequent, can pose challenges in diagnosis due to their nonspecific clinical presentation, often requiring biopsy for confirmation.
- A case study of a 64-year-old male with a 20-year history of scrotal swelling revealed it to be a cutaneous myxoma after surgical excision and histopathological analysis.
Article Synopsis
- Non-alcoholic steatohepatitis (NASH) is a serious illness with limited treatment options, and the FDA has recently approved resmetirom, a drug targeting the thyroid hormone receptor, for its treatment.
- In a review of four randomized controlled trials, resmetirom notably improved MRI-proton density fat fraction, reduced liver fat by 30%, and resolved NASH without fibrosis, although effects on certain liver enzymes were mixed.
- Resmetirom was linked to significant drops in various lipid levels (like triglycerides and LDL), but it also increased the likelihood of side effects such as diarrhea and nausea in patients.